Collegium (COLL) Q2 FY26 earnings call

Collegium Pharmaceutical delivered strong Q2 FY26 results, driven by significant growth in its ADHD business, particularly Jornet, and the successful integration of the Astaris acquisition. While the pain portfolio provided a durable cash flow base, Nucynta faced headwinds from authorized generic pricing. The company remains focused on expanding its ADHD presence, maximizing pain portfolio value, and disciplined capital deployment.